Pharmazac launched the new product Apregalin® / pregabalin for the treatment of peripheral and central neuropathic pain in adults, for epilepsy as adjunctive therapy in adults with partial seizures with or without secondary generalization and for the Generalized Anxiety Disorder in adults....
Pharmazac launched the new product Vasitimb / ezetimibe + simvastatin for theprevention of cardiovascular events, for hypercholesterlaemia and for theHomozygous Familial Hypercholesterolaemia. Therapeutic Indications Prevention of Cardiovascular Events Vasitimb is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome...
Pharmazac launched the new product Abelfiz / aripiprazole 10, 15 and 30mg in hard tablets for the treatment of schizophrenia in adults and in adolescents aged 15 years and older, for the treatment of moderate to severe manic episodes in bipolar I disorder and for...
Pharmazac participates in CPhI 2018.
Pharmazac has developed in its laboratories and launched in the Greek pharmaceutical market a nutraceutical, the titrate extract of Petasitis Hybridus in liquid hard gelatin capsules of 70,4 mg P A free, under the trade name Petagran. Petagran / Petasitis hybridus is effective in reducing the...
Pharmazac launched Etrozac / etoricoxib a selective cyclo-oxygenase – 2 (COX-2) inhibitor. Etrozac indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain and the pain sings of inflammation associated with acute gouty arthritis....
Pharmazac launched the new product Quental/quetiapine 50,200,300 and 400mg in prolonged release tablets for the treatment of schizophrenia and bipolar disorders....
Since February 14, 2018 our company is a regular member Hellenic Association of Pharmaceutical Companies...
Pharmazac launched the first Rosuvastatin generic in the Greek Pharmaceutical Market. Rosuvastatin is available in two forms of 14 and 30 film coated tablets and composition of 5mg, 10mg, 20mg and 40mg. Rosuvastain/Pharmazac is an HMG – CoA reductase inhibitor indicated for patients with primary hypercholesterolaemia or mixed...
